TLR7/8/9 agonists and low-dose cisplatin synergistically promotes tertiary lymphatic structure formation and antitumor immunity
Abstract In situ vaccination (ISV) triggers antitumor immune responses using the patient’s own cancer antigens, yet limited neoantigen release hampers its efficacy. Our novel combination therapy involves low-dose local cisplatin followed by ISV with a TLR7/8/9 agonist formulation (CR108), in which C...
Saved in:
Main Authors: | Shuting Wu, Rong Xiang, Yiwei Zhong, Shushu Zhao, Zhiyu Zhang, Zhihua Kou, Shijie Zhang, Yi Zhao, Cheng Zu, Gan Zhao, Yanling Xiao, Sulin Ren, Xiaoming Gao, Bin Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2025-01-01
|
Series: | npj Vaccines |
Online Access: | https://doi.org/10.1038/s41541-024-01055-z |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
De novo design of protein minibinder agonists of TLR3
by: Chloe S. Adams, et al.
Published: (2025-01-01) -
Akkermansia muciniphila Enhances the Antitumor Effect of Cisplatin in Lewis Lung Cancer Mice
by: Zhuo Chen, et al.
Published: (2020-01-01) -
Novel cisplatin-magnetoliposome complex shows enhanced antitumor activity via Hyperthermia
by: M. Carmen Jiménez-López, et al.
Published: (2025-02-01) -
Discovery of a non‐nucleotide stimulator of interferon genes (STING) agonist with systemic antitumor effect
by: Xiyuan Wang, et al.
Published: (2025-01-01) -
Synergistic Effect of Elastic Stockings to Maintain Volume Losses after Mechanical Lymphatic Therapy
by: José Maria Pereira de Godoy, et al.
Published: (2014-01-01)